Discussing NanoMabs as a Modular Platform for Next-Generation Bispecific & NanoMab-Drug Conjugates
- Defining the medical and technical unmet needs in bispecific antibodies and ADCs
- Addressing the unmet needs through NanoMab (nanobody-based) solutions
- Outlining the potential market impact and future implications of NanoMab-enabled therapeutics